Patient-reported nonadherence to HAART is related to protease inhibitor levels

Journal of Acquired Immune Deficiency Syndromes

Volumn 24, Issue 2, 2000, Pages 123-128

  Murri, Rita ^a   Ammassari, Adriana ^a   Gallicano, Keith ^b   De Luca, Andrea ^a   Cingolani, Antonella ^a   Jacobson, Denise ^c   Wu, Albert W ^d   Antinori, Andrea ^a,e  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF OTTAWA   (Canada)

^c TUFTS MEDICAL CENTER   (United States)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^e NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

Author keywords

Adherence; HAART; Plasma level; Protease inhibitors; Self report Drug monitoring

Indexed keywords

ANTIRETROVIRUS AGENT; INDINAVIR; PROTEINASE INHIBITOR; RITONAVIR;

ARTICLE; DRUG BLOOD LEVEL; FEMALE; HEALTH BEHAVIOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PATIENT MONITORING; PRIORITY JOURNAL; RETROVIRUS INFECTION; SELF REPORT;

EID: 0034209927     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200006010-00006     Document Type: Article

References (34)

1. Fatkenheuer G, Theisen A, Rochstroh J et al. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. AIDS 1997;11:F113-16.
2. Kaufmann D, Pantaleo G, Sudre P, Telenti A. CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Swiss HIV Cohort Study. Lancet 1998;7:351:723-4.
3. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services and Henry J. Kaiser Family Foundation. MMWR Morb Mortal Wkly Rep 1998;47:43-82.
4. Sackett DL, Snow JC. The magnitude of compliance and noncompliance. In: Haynes RB, Taylor DW, Sackett DL, eds. Compliance in health care. Baltimore: The Johns Hopkins University Press, 1979:11-21.
5. Mehta S, Moore RD, Graham NM. Potential factors affecting adherence with HIV therapy. AIDS 1997;15:1665-70.
6. Ickovics JR, Meisler AW. Adherence in AIDS clinical trials: a framework for clinical research and clinical care. J Clin Epidemiol 1997;50:385-91.
7. Eraker SA, Kirscht JP, Becker MH. Understanding and improving patient compliance. Ann Intern Med 1984;100:258-68.
8. Kastrissios H, Suarez JR, Hammer S, Katzenstein D, Blaschke TF. The extent of non-adherence in a large AIDS clinical trial using plasma dideoxynucleoside concentrations as a marker. AIDS 1998; 12:2305-11.
9. Kastrissios H, Suarez JR, Katzenstein D, Girard P, Sheiner LB, Blaschke TF. Characterizing patterns of drug-taking behavior with a multiple drug regimen in an AIDS clinical trial. AIDS 1998;12: 2295-2303.
10. Fletcher SW, Pappius EM, Harper SJ. Measurement of medication compliance in a clinical setting. Arch Intern Med 1979;139:635-8.
11. Haynes RB, Taylor W, Scakett DL, Gibson ES, Bernholz CD, Mukherjee J. Can simple clinical measurements detect patient noncompliance? Hypertension 1980;2:757-64.
12. Demasi R, Toison J, Pham S. et al. Self-reported adherence to HAART and correlation with HIV RNA: initial results with the Patient Medication Adherence Questionnaire [abstract 94]. Presented at the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, 1999.
13. Haubrich RH, Little SJ, Currier JS, et al. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. AIDS 1999;13:1099-1107.
14. Waterhouse DM, Calzone KA, Mele C, Brenner DE. Adherence to oral tamoxifen: a comparison of patient self-report, pill counts, and microelectronic monitoring. J Clin Oncol 1993;11:1189-97.
15. Paterson D, Swindells S, Mohr J, et al. How much adherence is enough? A prospective study of adherence to protease inhibitor therapy using MEMSCaps [abstract 92]. Presented at the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, 1999.
16. Golin C, Liu H, Hays R, et al. Self-reported adherence to protease inhibitors substantially overestimates an objective measure [abstract 95]. Presented at the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, 1999.
17. Bond W, Hussar DA. Detection methods and strategies for improving medication compliance. Am J Hosp Phann 1991;48:1978-88.
18. Eldred LJ, Wu AW, Chaisson RE, Moore RD. Adherence to antiretroviral and Pneumocystis prophylaxis in HIV disease. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18:117-25.
19. Hugen PWH, Verweij-van Wissen CPWGM, Burger DM, Wuis EW, Koopmans PP, Hekster YA. Simultaneous determination of the HIV-protease inhibitors indinavir, nelfinavir, saquinavir and ritonavir in human plasma by reversed-phase high-performance liquid chromatography. J Chromatogr Blamed Appl 1999;727: 139-49.
20. Wu AW, Rubin HR, Mathews WC, et al. A health status questionnaire using 30 items from the Medical Outcomes Study. Preliminary validation in persons with early HIV infection. Med Care 1991;29:786-98.
21. Walsh JC, Dalton M, Gazzard BG. Adherence to combination antiretroviral therapy assessed by anonymous patient self-report. AIDS 1998;12:2361-3.
22. Kaplan A, Golin C, Beck K, et al. Adherence to protease inhibitor therapy and viral load [abstract 96]. Presented at the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, 1999.
23. Hecht FM, Colfax G, Swanson M, Chesney MA. Adherence and effectiveness of protease inhibitors in clinical practice [abstract 151]. Presented at the 5th Conference on Retroviruses and Opportunistic Infections, Chicago, 1999.
24. Lopez-Suarez A, Fernandez-Gutierrez del Alamo C, Perez-Guzman E, Giron-Gonzalez JA. Adherence to the antiretroviral treatment in asymptomatic HIV-infected patients. AIDS 1998;12: 685-6.
25. Rodriguez-Rosado R, Jimenez-Nacher I, Soriano V, Anton P, Gonzalez-Lahoz J. Virological failure and adherence to antiretroviral therapy in HIV-infected patients. AIDS 1998;12:1112-13.
26. Griffith S. A review of the factors associated with patient compliance and the taking of prescribed medicines. Br J Gen Pract 1990; 40:114-16.
27. Coons SJ, Sheahan SL, Martin SS, Hendricks J, Robbins CA, Johnson JA. Predictors of medication noncompliance in a sample of older adults. Clin Ther 1994;16:110-17.
28. Broers B, Morabia A, Hirschel B. A cohort study of drug users' compliance with zidovudine treatment. Arch Intern Med 1994;154: 1121-7.
29. Carney R, Freedland K, Eisen S, Rich M, Jaffe A. Major depression and medication adherence in elderly patients with coronary artery disease. Health Psychol 1995;14:88-90.
30. Murri R, Ammassari A, De Luca A, Cingolani A, Antinori A. Definition and measurement of adherence to antiretroviral drugs in HIV-1-infected patients. Lancet 1999;5:353:1974.
31. Feinstein AR. On white-coat effects and the electronic monitoring of compliance. Arch Intern Med 1990;150:1377-8.
32. Grymonpre RE, Didur CD, Montgomery PR, Sitar DS. Pill count, self-report, and pharmacy claims data to measure medication adherence in the elderly. Ann Pharmacother 1998;32:749-54.
33. Piscitelli SC. The limited value of therapeutic drug monitoring in HIV infection. Accessed August 1999. Available at: www. medscape.com
34. Burger DM, Koopmans PP, Brinkman K, et al. Therapeutic drug monitoring of the HIV-protease inhibitor indinavir [abstract no. A-19]. Presented at the 37th International Conference on Antimicrobial Agents and Chemotherapy, Toronto, 1997.